Form 4: Hepion Pharmaceuticals Executive Buys Shares
Insider Transaction (Form 4)
Vincent S Lopriore, Executive Chairman and a Director of Hepion Pharmaceuticals, Inc., purchased 12,500,000 shares of common stock on September 3, 2026.
Summary
- Open-market purchase: acquired 12,500,000 Warrants on September 3, 2026; holds 22,500,000 after (Indirect).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $0, committing personal capital to the stock.
Insider Transactions
Vincent S Lopriore — Director, Officer (Executive Chairman)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-03 | Open-market purchase | Warrants | 12,500,000 | — | — | 22,500,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-03 | Open-market purchase (12,500,000 shares) |
Keywords
insider transaction, Form 4, HEPA, Hepion Pharmaceuticals, Inc., bullish, Vincent S Lopriore
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.